Full-Time

Associate Medical Director

Clinical Development

Beeline Medicines

Beeline Medicines

51-200 employees

Clinical-stage biotech developing precision autoimmune therapies

Compensation Overview

$242k - $313.5k/yr

+ Discretionary annual bonus + Long-term incentive award (equity)

Boston, MA, USA

Hybrid

Two days on-site per week required.

Master's, MBA, PhD, MD

Category
Medical, Clinical & Veterinary (1)

Get referred to Beeline Medicines

See people who can refer or advise you

Requirements
  • Education: Advanced clinical degree (MD or DO) or MD/PhD required
  • Board certification or clinical training in rheumatology, nephrology, immunology, or a related specialty strongly preferred
  • Minimum of 3 years of pharmaceutical / biotech industry experience or research / hospital setting in clinical development, medical monitoring, or drug safety
  • Direct experience treating, or managing lupus (SLE and/or CLE) and/or systemic sclerosis patients and clinical programs strongly preferred
  • Deep scientific expertise in autoimmune disease — rheumatology, specifically lupus (SLE and/or CLE) or systemic sclerosis, preferred
  • Deep clinical and scientific expertise in immunology and inflammation including knowledge of disease mechanisms, regulatory developments, and therapeutic approaches
  • Ability to lead and influence cross-functional teams in a matrixed, fast-paced biotech or pharmaceutical environment without direct line authority
  • Ability to build alignment across diverse internal and external stakeholders, including senior leadership, clinical operations, regulatory, and commercial partners
  • Track record of driving program-level decisions with clarity and accountability in resource-constrained settings
  • Experience fostering a culture of high performance, inclusion, and continuous learning
  • Occasional travel to medical congresses, KME meetings, advisory boards, and site engagements per business need
Responsibilities
  • Lead and provide medical oversight for assigned clinical trials including; protocol development, study conduct, medical monitoring, data review & interpretation, and clinical study reporting
  • Contribute to clinical development strategy and program plans by integrating scientific rationale, regulatory requirements, safety considerations, operational feasibility, and business objectives
  • Provide medical leadership on trial design, including endpoint selection, eligibility criteria, dose rationale, biomarker strategy, risk-based monitoring, and interim analysis frameworks
  • Monitor real time data collection throughout study conduct ensuring robust study conduct and protocol adherence
  • Support pharmacovigilance activities during trial conduct — monitor patient safety and benefit-risk throughout study conduct through review of adverse events, serious adverse events, laboratory data, safety narratives, and aggregate safety information, and contribute to related safety governance activities in coordination with the Global PV Medical Director
  • Serve as a key medical resource for investigative sites, external advisors, and clinical investigators, ensuring patients meet the appropriate eligibility criteria, responding to clinical and safety inquiries and supporting external interactions, advisory boards, and scientific communications as appropriate
  • Lead and conduct peer-to-peer scientific exchange with KMEs, investigators, and HCPs — sharing clinical and emerging data, discussing unmet medical needs, and gathering external insights that inform overall development strategy
  • Review, author, and contribute to key clinical and regulatory documents, including protocols, protocol amendments, investigator brochures, informed consent forms, clinical study reports, briefing materials, and health authority responses
  • Perform other duties and responsibilities as assigned
Desired Qualifications
  • Additional advanced degree (PhD, MPH, or MBA) is a plus
  • Experience treating, or managing lupus (SLE and/or CLE)and/or systemic sclerosis patients and clinical programs strongly preferred
  • Board certification or clinical training in rheumatology, nephrology, immunology, or a related specialty strongly preferred
  • Occasional travel to medical congresses, KME meetings, advisory boards, and site engagements per business need

Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.

Company Size

51-200

Company Stage

Series A

Total Funding

$426.3M

Headquarters

Stamford, Connecticut

Founded

2025

Get referred to Beeline Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million total.
  • Existing investors Bain Capital, CPP Investments, and BMS doubled down before Phase 2 data.
  • Management says pivotal lupus preparation has started, signaling confidence in a registrational path.

What critics are saying

  • Afimetoran's Phase 2 lupus readout in 2H 2026 is the company's defining binary event.
  • Merck KGaA's enpatoran missed the SLE endpoint in 2025, weakening the TLR7/8 thesis.
  • If afimetoran disappoints, Beeline's five-asset platform becomes a costly BMS asset recycle.

What makes Beeline Medicines unique

  • Beeline launched in April 2026 with five BMS-licensed programs, not discovery-stage science.
  • Afimetoran is a once-daily oral TLR7/8 inhibitor, designed for mechanistically precise lupus suppression.
  • Saqib Islam built SpringWorks into a $3.9 billion Merck KGaA acquisition in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Health Insurance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-12%

1 year growth

-12%

2 year growth

-12%
Beeline Medicines
Jun 30th, 2026
Terms of Use - Beeline Medicines

Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]

Fierce Biotech
Jun 29th, 2026
BMS-backed Beeline raises $126M series A extension for autoimmune programs

Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.

Yahoo Finance
Apr 15th, 2026
Beeline debuts with $300M and immune drugs licensed from Bristol Myers

Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.

Dealroom.co
Apr 15th, 2026
Beeline Medicines company information, funding & investors

Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.

GlobeNewswire
Apr 15th, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead...